A crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K<sub>α</sub> radiation at 15.1±0.2, 16.0±0.2, 0.4±0.2, 22.5±0.2, 27.3±0.2, 29.3±0.2 and 30.4±0.2. view more

The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting at least X-ray lines (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation at 8.2±0.2, 20.4±0.2, 21.7±0.2 and 25.5±0.2. view more

The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation essentially that provided in FIG. 1. view more

A solid pharmaceutical composition comprising, as an active ingredient, a crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K_α radiation at 15.1±0.2, 16.0±0.2, 18.9±0.2, 20.4±0.2, 22.5±0.2, 27.3±0.2, 29.3±0.2 and 30.4±0.2, and at least one suitable additive or auxiliary substance. view more

A method of treating a mammal suffering from pain, said method comprising administering to said mammal an effective analgesic amount of a 1-phenyl-3-dimethylaminopropane compound corresponding to formula I<chemistry id="CHEM-US-00044" wherein X represents OH, F, Cl, H or an OCOR⁶ group in which R⁶ is a C_1-3-alkyl group; R¹ is a C_1-4-alkyl group; R² represents H or a C_1-4-alkyl group and R³ represents H or a straight chain C_1-4-alkyl group, or R² and R³ together form a C_4-7 cycloalkyl radical, and R⁵ represents H, and R⁴ represents meta-O—Z, where Z is H, C_1-3-alkyl, PO(OC_1-4alkyl)₂, CO(OC_1-5-alkyl), CONH—C₆H₄—(C_1-3-alkyl) or CO—C₆H₄—R⁷, in which R⁷ is ortho-OCOC_1-3-alkyl or meta- or para-CH₂N(R⁸)₂, where R⁸ is C_1-4-alkyl or 4-morpholino, or R⁴ represents meta-S—C_1-3-alkyl, meta-Cl, meta-F, meta-CR⁹R¹⁰R¹¹, ortho-OH, ortho-O—C_2-3-alkyl, para-F or para-CR⁹R¹⁰R¹¹, where R⁹, R¹⁰ and R¹¹ independently represent H or F, or R⁵ represents para-Cl, para-F, para-OH or para-O—C_1-3-alkyl, and R⁴ represents meta-Cl, meta-F, meta-OH or meta-O—C_1-3-alkyl, or R⁴ and R⁵ together represent 3,4-OCH═CH— or 3,4-OCH═CHO—, or a salt thereof with a physiologically acceptable acid. view more

<?insert-start id="INS-S-00062" date="20070424" ?>61. (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride </i>(−<i>21</i>).<?insert-end id="INS-S-00062" ?>

<?insert-start id="INS-S-00118" date="20070424" ?>117. A method according to claim 8, wherein the compound is (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride view more

<?insert-start id="INS-S-00148" date="20070424" ?>147. A pharmaceutically acceptable salt of (−)-(<i>1R,2R</i>)-<i>3R</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol.<?insert-end id="INS-S-00148" view more